Arthur Becker is a New York real estate and technology investor whose office also serves as an art studio. He has created art throughout his life and displays his work, such as painting and sculptures, at his work. His office is just down the street from the first luxury property development he is solely handling on his own on 465 Washington Street in the Soho district. This development, when completed, will have 8 residential units and an overall estimated value of $52.5 million. More details can be found on Crunchbase.
Becker made his fortune in both the tech and financial industries. He was a stockbroker for Bear Stearns for many years. He is also the former CEO of two tech firms, NaviSite and Zino, LLC. He made his fortune buying tech companies in the first half of the 2000’s and afterward shifted to investing in real estate in both New York and Miami. Up until his new development, he has preferred to stay in the background on his real estate investments and let others be the face of the project.
In an article on The Real Deal, another property that Arthur Becker recently invested in was a project with four luxury townhouses on Sullivan Street. In exchange for his interest in the condo building that was also part of the project, Becker now owns three of the townhouses. He is investing $20 million into one of them, which he plans to live in, and plans to either sell or lease the other two.
Arthur Becker used to be married to Vera Wang, the fashion designer, before they separated in 2012. He had two daughters with Vera, who are now in their early 20’s. He was also a long-time senior advisor to her, advising her on the operations of her fashion empire. He is also a collector of different assets including ancient currencies, origami money boards, Magic 8 Ball’s, Paperweights, and other items.
It is through Madison Partners, LLC, that Becker invests in real estate. He serves as the organization’s Managing Member. He leads overall operations as well as directs investments into real estate projects and puts venture capital into startup biotechnology companies.